Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine

Flink H. J., Hansen B. E., Heathcote E. J., Feinman S. V., Simsek H., Karayalcin S., ...More

AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.101, no.11, pp.2523-2529, 2006 (SCI-Expanded) identifier identifier identifier


OBJECTIVES: Antiviral therapy leads to HBeAg seroconversion in 10-40% of the patients with HBeAg-positive chronic hepatitis B. Nonresponse may result in progression of liver disease and increased risk of hepatocellular carcinoma. As part of a global randomized controlled trial we investigated the efficacy (i.e., loss of HBeAg at the end of follow-up) of peginterferon alfa-2b (Peg-IFN alpha 2b) in patients who failed to respond to previous courses of standard interferon (IFN) or lamivudine.